Neurokinin-3 receptor antagonists in schizophrenia

Albert, Jeffrey S.; Potts, William

doi:10.1517/13543776.16.7.925

Cited by 6 publications

(2 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The layers were separated and the aqueous layer was extracted twice with 75 mL of Et 2 O. The combined organic layers were washed with 50 mL of saturated aqueous NH 4 Cl and 50 mL of saturated aq. NaHCO 3 and were then dried (Na 2 SO 4 ).…”

Section: Methodsmentioning

confidence: 99%

“…2 These treatments are generally thought to function by reducing dopamine neurotransmission through modulation of D2 receptors and tend to possess activity at multiple other targets including adrenergic, muscarinergic, histaminergic, and serotonergic (in particular 5-HT 2A ) receptors. 3,4 Because of this lack of efficacy especially in treating the negative and cognitive aspects of the disease and because of the side effect liabilities of these substances, considerable research effort has been focused on the discovery of alternative therapeutic targets beyond D2 receptor modulators. 5 One such mechanistic alternative is the NK3 receptor.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Synthesis of the NK3 receptor antagonist AZD2624 in C-14-, H-3- and C-13-labeled forms

Elmore

Dorff

Powell

et al. 2011

J Label Compd Radiopharm

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Synthesis of the NK3 receptor antagonist AZD2624 in C-14-, H-3- and C-13-labeled forms

Elmore

Dorff

Powell

et al. 2011

J Label Compd Radiopharm

View full text Add to dashboard Cite

Antipsychotic Agents

Brown¹,

Li²,

Sinz³

2010

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

The medicinal chemistry of antipsychotic agents is reviewed in this chapter. The definition of schizophrenia is summarized in two categories, namely, symptom domains and pathology. An overview is given for antipsychotic medications including their clinical applications and side effects. This chapter also describes many animal models for schizophrenia. After an introduction of the FDA approved antipsychotic drugs, the structure–activity relationship, pharmacokinetics, biotransformation, and drug–drug interactions are discussed for both conventional and atypical antipsychotics in details. Finally, eight different strategies for drug discovery of antipsychotics are delineated.

show abstract